A-582941, cholinergic alpha 7 nicotinic receptor agonist, improved cognitive and negative symptoms of the sub-chronic MK-801 model of schizophrenia in rats

Creative Commons License

Unal G. , Aricioglu F.

PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY, cilt.28, ss.4-13, 2018 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 28 Konu: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1080/24750573.2017.1379716
  • Sayfa Sayıları: ss.4-13


OBJECTIVES: Nicotinic receptor systems are involved in a wide variety of behavioural functions, including cognitive function, and nicotinic medications, may provide beneficial treatment for cognitive dysfunctions such as schizophrenia. According to the results of postmortem studies of schizophrenic patients, alpha 7 nicotinic acethylcholine receptor (alpha 7 NAChR) binding levels and protein expressions were found to be decreased in cognition-related areas such as hippocampus and prefrontal cortex. In addition to this the fact that the prevalence of tobacco consumption is greater than healthy individuals encouraged research of nicotinic receptors in schizophrenia pathogenesis and treatment. In this study, we examined the effect of A-582941, a partial agonist of alpha 7 NAChR, in the sub-chronic MK-801 model of schizophrenia in rats.